Ahmed, I., Elwakeel, L., Tawfik, A., Abdel-Malek, R. (2019). Oxaliplatin-Induced Peripheral Neuropathy Grade in Females with Colorectal Cancer Patients. Archives of Pharmaceutical Sciences Ain Shams University, 3(1), 116-122. doi: 10.21608/aps.2019.10411.2020
Inas Moawya Ahmed; Lamia Elwakeel; Amr S. Tawfik; Raafat Ragaie Abdel-Malek. "Oxaliplatin-Induced Peripheral Neuropathy Grade in Females with Colorectal Cancer Patients". Archives of Pharmaceutical Sciences Ain Shams University, 3, 1, 2019, 116-122. doi: 10.21608/aps.2019.10411.2020
Ahmed, I., Elwakeel, L., Tawfik, A., Abdel-Malek, R. (2019). 'Oxaliplatin-Induced Peripheral Neuropathy Grade in Females with Colorectal Cancer Patients', Archives of Pharmaceutical Sciences Ain Shams University, 3(1), pp. 116-122. doi: 10.21608/aps.2019.10411.2020
Ahmed, I., Elwakeel, L., Tawfik, A., Abdel-Malek, R. Oxaliplatin-Induced Peripheral Neuropathy Grade in Females with Colorectal Cancer Patients. Archives of Pharmaceutical Sciences Ain Shams University, 2019; 3(1): 116-122. doi: 10.21608/aps.2019.10411.2020
Oxaliplatin-Induced Peripheral Neuropathy Grade in Females with Colorectal Cancer Patients
1Department of Clinical Pharmacy, Faculty of Pharmacy Ain Shams University, Cairo, Egypt
2Department of Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt
Abstract
The oxaliplatin-based regimen is considered an important standard of care for patients with colon cancer (CC). Neurotoxicity is the most relevant non-hematologic toxicity of oxaliplatin. The current study aimed to assess the association between colorectal cancer patient's (CRC) gender and susceptibility of oxaliplatin-induced sensory and motor peripheral neuropathy grades in Egyptian patients. All eligible patients between 18-75 years old with CRC were included in the study and only those who had a neurologic disease or diseases impairing neurologic function were excluded. Then eligible patients were stratified into two groups according to gender; oxaliplatin-induced peripheral neuropathy (OIPN) was evaluated and graded on day 1 of each chemotherapy cycle for 12 cycles according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0 from March 2015 to October 2017. From a total of 47 females and 33 males; 41(87.2%) females and 29 (87.9%) males suffered from different grades of sensory and motor peripheral neuropathy.Regarding sensory oxaliplatin-induced peripheral neuropathy (OIPN), females had a higher risk of grade II-III PN than males (92.7% versus 58.6% respectively; p =0.001) For motor OIPN, females were more susceptible to grade II-III PN versus males (84.6% versus 56.5% respectively; p=0.015). In conclusion, High grade (grade II-III) Oxaliplatin-induced sensory and motor peripheral neuropathy occurred more frequently in females versus males Egyptian colorectal cancer patients.
Top